Axiom is dedicated to empowering scientists to eliminate molecular toxicity by providing the most accurate and affordable predictive models. Leveraging a unique dataset of more than 100,000 molecules tested in pooled primary human liver cells, Axiom's ML/AI models surpass conventional toxicity screening methods by offering higher sensitivity and specificity in hazard detection. The platform also integrates mechanistic cell-based data (mitochondrial toxicity, ER stress, ROS formation, cytotoxicity, and more) with clinical adverse outcomes to deliver precise risk assessments at relevant exposure levels. Axiom's ML/AI models run solely on the molecular structure, removing the need for costly physical experiments. As a result, scientists can affordably identify toxic substructures and be guided toward safer molecule design, ultimately accelerating the development of more effective and less toxic therapeutics.
AxiomBio, Inc.
Axiom provides accurate, affordable predictive models that integrate cell-based toxicity data with clinical outcomes for precise ML/AI-driven risk assessments.
